Sisu Pharma exploits cellular stress by directly targeting Heat Shock Factor 1 (HSF1), the central regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology and therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases